Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect various organs and tissues in the body.
The exact cause of SLE is not well understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors. Certain genes may predispose individuals to develop SLE, and hormonal factors, such as estrogen, are thought to play a role; SLE is more prevalent in women than in men. As in other autoimmune diseases, inflammation is the primary immune response to auto-antigens, and tissue damage in SLE can affect a wide range of organs, including the skin, joints, kidneys, heart, lungs, brain, blood cells, and other tissues.
The symptoms of SLE can vary widely and may include joint pain and swelling, skin rashes (especially a characteristic butterfly-shaped rash on the face), fatigue, fever, chest pain, photosensitivity (sensitivity to sunlight), and mouth ulcers. SLE can also cause complications such as kidney damage, cardiovascular problems, and neurological disorders.
Current treatments for SLE are palliative, attempting to control symptoms, prevent flares, and minimize organ damage. The treatment regimen is similar to that of other chronic inflammatory conditions, often involving a combination of medications that includes NSAIDs, corticosteroids, immunosuppressants, and biologic therapies.
Tregs have the ability to suppress immune responses and prevent the immune system from attacking the body’s own tissues and the TILAC™ approach is perfectly designed to promote the expression of these cells that are specific for implicated self-antigens.
Clinical trials are need to evaluate the potential of the TILAC™ approach, and investigators are urged to contact us for further discussion.